(Q84314306)

English

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial

scientific article published on 06 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

7

object named as

Hoon Kyo Kim

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

9

object named as

Yeul Hong Kim

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Jong-Mu Sun

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Ki Hyeong Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sang-We Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Dae Ho Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Young Joo Min

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Hong Suk Song

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Bong-Seog Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

In Gyu Hwang

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Keehyun Lee

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sook Jung Jo

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Jae Won Lee

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Jin Seok Ahn

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Keunchil Park

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Myung-Ju Ahn

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Korean Cancer Study Group

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

6 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

6234-6242

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27630

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27630

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674612%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84314306&oldid=2169609489"